An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C

This prospective, multicenter, observational cohort study will evaluate the efficacy and safety of pegylated interferon alfa (peginterferon alfa) (e.g. Pegasys) plus ribavirin and treatment regimens containing direct-acting antivirals in participants with chronic hepatitis C who are treatment-naïve or treatment-experienced and HIV HCV co-infected. Data will be collected from participants receiving treatment according to current Summary of Product Characteristics (SPC) and local labeling for the duration of their treatment and a 24-week follow-up.

Study Overview

• Status: Completed
• Conditions: Hepatitis C, Chronic
• Intervention / Treatment: Drug: Peg-IFN Alfa-2a; Drug: Ribavirin; Drug: Peg-IFN Alfa-2b; Drug: Boceprevir; Drug: Telaprevir

• Study Type: Observational
• Enrollment (Actual): 4442

Contacts and Locations

Study Locations

• Belgium
  • Antwerpen, Belgium, 2060
  • Antwerpen, Belgium, 2018
  • Bouge, Belgium, 5004
  • Brussels, Belgium, 1000
  • Bruxelles, Belgium, 1020
  • Bruxelles, Belgium, 1070
  • Bruxelles, Belgium, 1200
  • Bruxelles, Belgium, 1180
  • Bruxelles, Belgium, 1190
  • Edegem, Belgium, 2650
  • Gent, Belgium, 9000
  • Gilly (Charleroi), Belgium, 6000
  • Hasselt, Belgium, 3500
  • Heusy, Belgium, 4802
  • Kortrijk, Belgium, 8500
  • Leuven, Belgium, 3000
  • Liège, Belgium, 4000
  • Mons, Belgium, 7000
  • Montignies sur Sambre, Belgium, 6061
  • Namur, Belgium, 5000
  • Oostende, Belgium, 8400
  • Roeselare, Belgium, 8800
  • Verviers, Belgium, 4800
• Egypt
  • Alexandria, Egypt
  • Alexandria, Egypt
  • Cairo, Egypt
  • Cairo, Egypt
  • Giza, Egypt
  • Tanta, Egypt
• Estonia
  • Kohtla-Järve, Estonia, 31025
  • Pärnu, Estonia, 80010
  • Tallinn, Estonia, 10617
  • Tallinn, Estonia, 10138
  • Tartu, Estonia, 51014
• France
  • Aix En Provence, France, 13616
  • Amiens, France, 80054
  • Argenteuil, France, 95107
  • Avignon, France, 84902
  • Besancon, France, 25000
  • Besancon, France, 25030
  • Beziers, France, 34500
  • Boulogne Billancourt, France, 92104
  • Bourgoin Jallieu, France, 38300
  • Caen, France, 14033
  • Chambray Les Tours, France, 37171
  • Clichy, France, 92118
  • Creil, France, 60109
  • Creteil, France, 94010
  • Epinay-Sur-Seine, France, 93806
  • Evry, France, 91014
  • Freyming Merlebach, France, 57804
  • Gonesse, France, 95503
  • Grasse, France, 06130
  • Hyeres, France, 83407
  • La Tronche, France, 38700
  • Lagny Sur Marne, France, 77405
  • Lille, France, 59037
  • Limoges, France, 87042
  • Lomme, France, 59462
  • Lyon, France, 69009
  • Mantes La Jolie, France, 78200
  • Marseille, France, 13285
  • Meaux, France, 77104
  • Montpellier, France, 34295
  • Montpellier, France, 34070
  • Nice, France, 06202
  • Nimes, France, 30029
  • Orange, France, 84100
  • Orleans, France, 45100
  • Paris, France, 75970
  • Paris, France, 75908
  • Paris, France, 75651
  • Paris, France, 75571
  • Paris, France, 75679
  • Pau, France, 64046
  • Perpignan, France, 66046
  • Pessac, France, 33604
  • Reims, France, 51092
  • Rennes, France, 35033
  • Rouen, France, 76031
  • Saint Nazaire, France, 44606
  • St Laurent Du Var, France, 06700
  • St Priest En Jarez, France, 42277
  • Strasbourg, France, 67091
  • Suresnes, France, 92151
  • Toulon, France, 83000
  • Toulouse, France, 31059
  • Tourcoing, France, 59208
  • Vandoeuvre-les-nancy, France, 54511
  • Vannes, France, 56017
  • Villejuif, France, 94804
  • Villeneuve Maguelone, France, 34751
  • Villeneuve St Georges, France, 94195
• Germany
  • Aachen, Germany, 52074
  • Berlin, Germany, 10777
  • Berlin, Germany, 10243
  • Burghausen, Germany, 84489
  • Düsseldorf, Germany, 40237
  • Erlangen, Germany, 91054
  • Essen, Germany, 45122
  • Kassel, Germany, 34117
  • Köln, Germany, 50937
  • Lübeck, Germany, 23562
  • Magdeburg, Germany, 39120
  • Mannheim, Germany, 68167
  • Rostock, Germany, 18057
  • Rottenburg, Germany, 72108
  • Tübingen, Germany, 72076
• Greece
  • Alexandroupolis, Greece, 68100
  • Athens, Greece, 115 27
  • Athens, Greece, 11527
  • Athens, Greece, 11522
  • Ioannina, Greece, 455 00
  • Larissa, Greece, 41 110
  • Nea Kifissia, Greece, 14564
  • Patra, Greece, 265 04
  • Thessaloniki, Greece, 546 42
• Hungary
  • Ajka, Hungary, H-8400
  • Balassagyarmat, Hungary, 2660
  • Bekescsaba, Hungary, 5600
  • Budapest, Hungary, 1083
  • Budapest, Hungary, 1088
  • Budapest, Hungary, 1097
  • Budapest, Hungary, H-1125
  • Budapest, Hungary, 1067
  • Budapest, Hungary, 1126
  • Debrecen, Hungary, 4032
  • Debrecen, Hungary, H-4031
  • Gyula, Hungary, 5700
  • Kaposvar, Hungary, 7400
  • Kecskemet, Hungary, 6000
  • Miskolc, Hungary, H-3501
  • Nyíregyháza, Hungary, 4400
  • Pecs, Hungary, 7624
  • Sopron, Hungary, 9400
  • Szeged, Hungary, 6720
  • Szekesfehervar, Hungary, 8000
  • Szolnok, Hungary, 5000
  • Szombathely, Hungary, 9700
  • Székesfehérvár, Hungary, 8000
  • Tatabánya, Hungary, 2800
  • Zalaegerszeg, Hungary, 8900
  • Zalaegerszeg, Hungary, 8901
• Ireland
  • Dublin, Ireland, 4
  • Dublin, Ireland, 9
  • Dublin, Ireland, 8
• Italy
  • Abruzzo
    • Chieti, Abruzzo, Italy, 66013
  • Calabria
    • Reggio Calabria, Calabria, Italy, 89100
  • Campania
    • Avellino, Campania, Italy, 83100
    • Gragnano, Campania, Italy, 80054
    • Marcianise, Campania, Italy, 81025
    • Napoli, Campania, Italy, 80131
    • Napoli, Campania, Italy, 80138
    • Napoli, Campania, Italy, 80136
    • Nocera Inferiore, Campania, Italy, 84014
    • Nola, Campania, Italy, 80035
  • Emilia-Romagna
    • Bologna, Emilia-Romagna, Italy, 40138
    • Modena, Emilia-Romagna, Italy, 41100
    • Parma, Emilia-Romagna, Italy, 43126
    • Piacenza, Emilia-Romagna, Italy, 29121
  • Friuli-Venezia Giulia
    • Udine, Friuli-Venezia Giulia, Italy, 33100
  • Lazio
    • Roma, Lazio, Italy, 00165
    • Roma, Lazio, Italy, 00152
    • Roma, Lazio, Italy, 00161
    • Roma, Lazio, Italy, 00149
    • Roma, Lazio, Italy, 00189
  • Liguria
    • Genova, Liguria, Italy, 16132
    • Savona, Liguria, Italy, 17100
  • Lombardia
    • Busto Arsizio, Lombardia, Italy, 21052
    • Milano, Lombardia, Italy, 20132
    • Milano, Lombardia, Italy, 20157
    • Milano, Lombardia, Italy, 20122
    • Milano, Lombardia, Italy, 20162
    • Milano, Lombardia, Italy, 20123
    • Milano, Lombardia, Italy, 20142
  • Marche
    • Torrette Di Ancona, Marche, Italy, 60020
  • Piemonte
    • Biella, Piemonte, Italy, 13900
    • Cuorgnè (TO), Piemonte, Italy, 10082
    • Omegna (VB), Piemonte, Italy, 28887
  • Puglia
    • Bari, Puglia, Italy, 70124
    • Bisceglie, Puglia, Italy, 70052
    • Castellana Grotte, Puglia, Italy, 70013
    • San Giovanni Rotondo, Puglia, Italy, 71013
  • Sardegna
    • Cagliari, Sardegna, Italy, 09042
    • Cagliari, Sardegna, Italy, 09100
    • Sassari, Sardegna, Italy, 07100
  • Sicilia
    • Catania, Sicilia, Italy, 95100
    • Catania, Sicilia, Italy, 95126
    • Messina, Sicilia, Italy, 98124
    • Palermo, Sicilia, Italy, 90127
  • Toscana
    • Arezzo, Toscana, Italy, 52100
    • Firenze, Toscana, Italy, 50134
    • Livorno, Toscana, Italy, 57124
  • Veneto
    • Padova, Veneto, Italy, 35128
• Kuwait
  • Safat, Kuwait, 13041
• Lebanon
  • Baabda, Lebanon, 50
  • Beirut, Lebanon, 99999
  • Beirut, Lebanon, 11-236
  • Beirut, Lebanon
  • Nabatieh, Lebanon
  • Tripoli, Lebanon, 371 Tripoli
• Macedonia, The Former Yugoslav Republic of
  • Skopje, Macedonia, The Former Yugoslav Republic of, 1000
• Morocco
  • Casablanca, Morocco, 20100
  • Casablanca, Morocco
  • Casablanca, Morocco, 20000
  • Fes, Morocco
  • Marrakech, Morocco
  • Rabat, Morocco, 504
  • Rabat, Morocco, 62000
• Oman
  • Muscat, Oman, P.O Box 35
• Pakistan
  • Faisalabad, Pakistan
  • Gujranwala, Pakistan
  • Karachi, Pakistan
  • Lahore, Pakistan, 20021
  • Lahore, Pakistan
  • Rawalpindi, Pakistan
• Portugal
  • Almada, Portugal, 2805-267
  • Amadora, Portugal, 2700-020
  • Aveiro, Portugal, 3810-096
  • Beja, Portugal, 7801-849
  • Coimbra, Portugal, 3041-801
  • Faro, Portugal, 8000-386
  • Lisboa, Portugal, 1649-035
  • Lisboa, Portugal, 1349-019
  • Porto, Portugal, 4099-001
• Qatar
  • Doha, Qatar, P.O.Box 3051
• Romania
  • Bucharest, Romania, 021105
  • Bucharest, Romania, 022328
  • Cluj-napoca, Romania, 400162
  • Constanta, Romania
  • Iasi, Romania, 700554
  • Iasi, Romania, 700620
  • Timisoara, Romania, 300167
• Saudi Arabia
  • Holy Makkah, Saudi Arabia, 21583-Makkah P.O.Box-53356
  • Riyadh, Saudi Arabia, 11211
  • Riyadh, Saudi Arabia, 11159
• Serbia
  • Belgrade, Serbia, 11000
  • Novi Sad, Serbia, 21000
• Sweden
  • Gävle, Sweden, 80187
  • Karlstad, Sweden, 65185
  • Uppsala, Sweden, 75185
• Switzerland
  • Lugano, Switzerland, 6900
  • St. Gallen, Switzerland, 9007
• Syrian Arab Republic
  • Aleppo, Syrian Arab Republic, 6448
• Taiwan
  • Kaohsiung, Taiwan, 00833
  • Kaohsiung, Taiwan, 807
  • Taichung, Taiwan, 40447
  • Taipei, Taiwan, 100
  • Taipei, Taiwan, 112
  • Taoyuan, Taiwan, 333
• Turkey
  • Adana, Turkey, 01100
  • Ankara, Turkey
  • Ankara, Turkey, 06100
  • Ankara, Turkey, 06290
  • Ankara, Turkey, 06800
  • Hatay, Turkey, 31040
  • ISTANBULt, Turkey
  • Istanbul, Turkey, 34390
  • Izmir, Turkey, 35100
  • Kayseri, Turkey, 38039
  • Mersin, Turkey, 33169
  • Tokat, Turkey, 60250
  • Trabzon, Turkey, 61080
• United Arab Emirates
  • Al Ain, United Arab Emirates, P.O.Box 1006
  • Dubai, United Arab Emirates, 4545
  • Sharjah, United Arab Emirates, P.O.Box: 5735 - Sharjah, UAE
• United Kingdom
  • Dundee, United Kingdom, DD1 9SY
  • Hull, United Kingdom, HU3 2JZ
  • London, United Kingdom, W2 1NY
  • London, United Kingdom, E1 1BB
  • Manchester, United Kingdom, M8 5RB
  • Nottingham, United Kingdom, NG7 2UH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Chronic hepatitis C (CHC) participants (naïve or treatment experienced, including HIV HCV co-infected) receiving combination therapy with pegylated interferons plus ribavirin or treatment regimens containing direct-acting antivirals.

Description

Inclusion Criteria:

• Adult (according to local legislation) participants
• Chronic hepatitis C (HCV)
• Naive or treatment experienced, HIV-HCV co-infected or HCV mono-infected
• Receiving treatment for HCV with pegylated interferons plus ribavirin or regimens containing direct-acting antivirals (DAA) according to standard of care and in line with current SPC/local labeling

Exclusion Criteria:

• Contraindications according to SPC/local labeling
• Treatment started >4 weeks before entering study

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Dual Therapy: Peg-IFN Alfa-2a + Ribavirin; Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Peg-IFN Alfa-2a; Peg-IFN Alfa-2a according to standard of care and in line with local labeling.; Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.
Dual Therapy: Peg-IFN Alfa-2b + Ribavirin; Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.; Drug: Peg-IFN Alfa-2b; Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin; Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Peg-IFN Alfa-2a; Peg-IFN Alfa-2a according to standard of care and in line with local labeling.; Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.; Drug: Boceprevir; Boceprevir according to standard of care and in line with local labeling.
Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin; Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.; Drug: Peg-IFN Alfa-2b; Peg-IFN Alfa-2b according to standard of care and in line with local labeling.; Drug: Boceprevir; Boceprevir according to standard of care and in line with local labeling.
Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin; Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Peg-IFN Alfa-2a; Peg-IFN Alfa-2a according to standard of care and in line with local labeling.; Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.; Drug: Telaprevir; Telaprevir according to standard of care and in line with local labeling.
Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin; Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.	Drug: Ribavirin; Ribavirin according to standard of care and in line with local labeling.; Drug: Peg-IFN Alfa-2b; Peg-IFN Alfa-2b according to standard of care and in line with local labeling.; Drug: Telaprevir; Telaprevir according to standard of care and in line with local labeling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)	SVR24 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (<) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [<=] 50 IU/mL) at 24 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be <=50 IU/mL. SVR24 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection <= 50 IU/mL at 24 weeks post completion of the treatment period.	24 weeks after end of treatment (up to 118 weeks)
Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)	SVR12 rate for dual therapy participants is defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (<) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [<=] 50 IU/mL) at 12 weeks post completion of the treatment period. If a quantitative test was used, the lower limit of quantification had to be <=50 IU/mL. SVR12 for triple therapy participants is defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection <= 50 IU/mL at 12 weeks post completion of the treatment period.	12 weeks after end of treatment (up to 118 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Virological Response at Various on Treatment Time Points and End of Treatment (EOT)	Virological response (VR) for dual therapy participants is defined as HCV RNA <50 IU/mL as assessed by a qualitative HCV RNA test with a lower limit of detection (LLD) <=50 IU/mL or as assessed by a quantitative test with a lower limit of quantification (LLQ) <=50 IU/mL for all time points concerned. Results of HCV RNA tests with LLD and LLQ >50 IU/mL were considered as non-response. VR for triple therapy participants is defined as undetectable HCV RNA assessed by a test with lower limit of detection <=50 IU/mL (UVR). Results of HCV RNA tests with an LLD >50 IU/mL were considered as non-response for triple therapy participants.	Week 4, 12 and End of treatment (EOT) (up to 96 weeks)
Virological Relapse After End of Treatment	Virological relapse defined as non-virological response (non-VR)/non-undetectable virological response (non-UVR) at the last HCV RNA assessment during the treatment-free follow-up period in participants with VR/UVR at EOT. Here, number of participants analyzed is the participants with end of treatment response (EoT-R) who also had an HCV RNA test at least 12 weeks after EoT or whose last follow-up HCV RNA test showed non-response (HCV RNA >=50 IU/mL).	Up to 24 weeks after EOT (up to 118 weeks)
Virological Breakthrough	Virological breakthrough/rebound defined as non-VR/non-UVR during the treatment period (including end of treatment) in participants with prior VR/UVR or an increase of HCV RNA by >=1 log10 during the treatment period in comparison to the lowest HCV RNA (nadir) previously measured during the treatment period in participants without VR/UVR during the treatment period. Here, Number of participants analyzed is the participants with at least 2 on-treatment HCV RNA assessments (including EoT) or 1 on-treatment HCV RNA assessment (excluding EoT) and response at EoT by backward imputation.	Up to EOT (up to 118 weeks)
Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions	SVR 12 and 24 rates for dual therapy participants are defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) less than (<) 50 international unit/milliliters (IU/mL) (as measured by a commercially available HCV RNA test with lower limit of detection less than or equal to [<=] 50 IU/mL) at 12 or 24 weeks post completion of the treatment period. If a qualitative test was used, then the lower limit of detection has to be <=50 IU/mL. SVR12 and 24 rates for triple therapy participants are defined as percentage of participants with undetectable HCV RNA assessed by a test with lower limit of detection <= 50 IU/mL at 12 or 24 weeks post completion of the treatment period. Here, number of participants analyzed excluded the participants with premature withdrawal due to lack of efficacy or non-safety reasons and participants without dose reductions or interruptions during the first 99 study days.	Up to first 12 weeks of treatment
Percentage of Participants With Very Rapid Virological Response, Rapid Virological Response, Complete Early Virological Response and Partial Early Virological Response (pEVR) During First 12 Weeks	Percentage of participants with very rapid virological response (VRVR) (defined as VR/UVR by study week 2), rapid virological response (RVR) (defined as VR/UVR by study week 4, but no VRVR), complete early virological response (cEVR) (defined as VR/UVR by study week 12, but no VRVR or RVR) and partial early virological response (pEVR) (defined as a 2 log10 drop of HCV RNA by study week 12, but no VRVR, RVR or cEVR) were reported.	Up to 12 weeks
Percentage of Participants Achieving Extended (Rapid) Virological Response (eRVR)	Extended (rapid) virological response (eRVR) defined as UVR at weeks 4 and 12 for telaprevir, and as UVR at weeks 8 and 24 for boceprevir.	Up to 98 weeks
Duration of Overall Treatment	Duration of overall treatment was defined as the time between first and last administration of any study drug, in weeks.	Up to 118 weeks
Percentage of Participants Treated According to Label/Summary of Product Characteristics (SPC)		Up to 118 weeks
Percentage of Participants Who Discontinued Treatment With PEG-IFN and Ribavirin (RBV)	Participants who prolonged the treatment period from 72 weeks were not reported.	Up to 72 weeks of treatment
Percentage of Participants Who Discontinued Treatment With Direct-Acting Anti-viral (DAA)	Participants who prolonged the treatment period from 72 weeks were not reported. Participants who discontinued their treatment as planned were included. Here, number of participant analyzed is the total number of participants who received direct-acting anti-viral (DAA).	Up to 72 weeks of treatment
Percentage of Participants With Concomitant Medical Condition at Baseline		Baseline
Percentage of Participants With Adverse Events (AE)	An AE was defined as any adverse medical event that occurred after the participant used the investigational medicinal product (IMP) or other intervention behaviors specified by the protocol in the clinical trial regardless of relationship to the study treatment.	Up to 118 weeks

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start: September 1, 2011
• Primary Completion (Actual): July 1, 2015
• Study Completion (Actual): July 1, 2015

Study Registration Dates

• First Submitted: October 4, 2011
• First Submitted That Met QC Criteria: October 5, 2011
• First Posted (Estimate): October 6, 2011

Study Record Updates

• Last Update Posted (Actual): March 30, 2017
• Last Update Submitted That Met QC Criteria: February 10, 2017
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis; Hepatitis A; Hepatitis C; Hepatitis C, Chronic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Antimetabolites; Antineoplastic Agents; Immunologic Factors; Interferon-alpha; Ribavirin; Peginterferon alfa-2a; Interferon alpha-2; Interferon-alfa-1b; Peginterferon alfa-2b
• Other Study ID Numbers: MV25599